UnknownNot Applicable

Assessment of Blood Coagulation Disorders in Patients With Pulmonary Hypertension

Greece60 participantsStarted 2015-03-12

Plain-language summary

The objective of the present study is to assess blood coagulation disorders in patients with Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension. The investigators aim to evaluate any possible coagulation abnormalities related to the patients' primary disease and any possible effects the pulmonary hypertension- specific therapy may have on hemostasis.

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Pulmonary Arterial Hypertension, * Chronic Thromboembolic Pulmonary Hypertension. Exclusion Criteria: * renal insufficiency, * hepatic insufficiency, * thyroid dysfunction, * malignancy, * active infections, * receiving anticoagulant or antiplatelet therapy, * history of hemostatic disorders irrelevant to their primary disease, * abnormal red blood counts.

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

PFA-100 in detection of platelet abnormalities in PAH and CTEPH patients.

Timeframe: 6 months

Light transmission aggreggometry in detection of platelet abnormalities in PAH and CTEPH patients.

Timeframe: 6 months

ROTEM in detection of coagulation abnormalities in PAH and CTEPH patients.

Timeframe: 6 months

Endogenous thrombin potential in detection of thrombin abnormalities in PAH and CTEPH patients.

Timeframe: 6 months

Trial details

NCT IDNCT03195543

SponsorNational and Kapodistrian University of Athens

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2020-12

Contact for this trial

Eleni Vrigkou, MD, MSc

00302105832179 elenivrigkou@gmail.com

View on ClinicalTrials.gov More Pulmonary Artery Hypertension trials

Plain-language summary

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

What they're measuring

PFA-100 in detection of platelet abnormalities in PAH and CTEPH patients.

Timeframe: 6 months

Light transmission aggreggometry in detection of platelet abnormalities in PAH and CTEPH patients.

Timeframe: 6 months

ROTEM in detection of coagulation abnormalities in PAH and CTEPH patients.

Timeframe: 6 months

Endogenous thrombin potential in detection of thrombin abnormalities in PAH and CTEPH patients.

Timeframe: 6 months